Gingrich R D, Burns C P, Armitage J O, Aunan S B, Edwards R W, Dick F R, Maguire L C, Leimert J T
Cancer Treat Rep. 1985 Feb;69(2):153-60.
An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (greater than 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be greater than 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.
针对成人急性淋巴细胞白血病（ALL）设计了一项具有治愈意图的强化治疗方案。连续48例患者接受了该方案治疗，其中39例（81%）获得完全缓解。尽管无细胞和T细胞疾病患者的完全缓解率都很高，但无细胞白血病患者的中位缓解期（超过306周）明显长于T细胞疾病患者（62周）。通过生命表分析，48例患者的中位生存期预计超过310周，5例患者已完成3年治疗方案，停止治疗1至3年，疾病未复发。根据免疫标志物状态对成人ALL进行分类是一项重要且易于实施的治疗前操作，可识别出在接受本研究所述方案治疗时预后显著不同的患者亚组。白血病细胞具有T细胞特征的患者中位缓解期较短。最重要的是，该治疗方案通过治疗反应识别出一部分成人ALL患者，其白血病原始细胞的特征是缺乏免疫标志物，而且相当一部分患者似乎有潜在治愈的可能。
